Docket Number:28A-1040714
Inventor:Shie-Liang Hsieh, Henrich Cheng, Wen-Hung Huang, Chuan-Wen Chiu, Shao-Ji Lin
IP Status:USP Application
Abstract:
Spinal cord injury (SCI) causes loss of neurons and axons resulting in motor and sensory function impairments. SCI elicits an inflammatory response and induces infiltration of immune cells, predominantly macrophages, to the injured site. DcR3, a member of the tumor necrosis factor receptor (TNFR) superfamily, is an immunomodulatory protein affecting immune response and has been shown possessing an ability to elevate the anti-inflammatory/repairing macrophage (M2)-like phenotype.
Fields of Application:
These beneficial effects of DcR3 on SCI suggest DcR3 as a therapeutic option for SCI patients in the future.
Advantages when compared to the existing technologies:
DcR3 have not been evaluated in the central nerve system, specifically in the spinal cord injury. In this study, we demonstrate that intrathecal administration of soluble recombinant human DcR3 proteins significantly reduced secondary injury pathology and improved recovery of locomotor function with smaller wound cavity at the epicenter in Sprague-Dawley (SD) rats after contused spinal cord injury at the T9 level.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
